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Abstract
Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but
recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of
MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of
the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas
of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the
same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through
pharmacologic stabilization or genetic ablation of MCs in recipients mice, we showed that MCs promote WD
adenocarcinoma growth but are dispensable for PD tumors. WD tumors rely on MCs for matrix metalloprotease
9 (MMP-9) provision, as reconstitution of MC-deficient mice with wild-type but not MMP-9/ MCs was
sufficient to promote their growth. In contrast, PD tumors are MMP-9 self-competent, consistently with
epithelial-to-mesenchymal transition. Such a dual source of MMP-9 was confirmed in human tumors, suggesting
that MCs could be a good target for early-stage prostate cancer. Interestingly, in testing whether MC targeting
could block or delay tumorigenesis in tumor-prone TRAMP mice, we observed a high incidence of early and
aggressive tumors, characterized by a neuroendocrine (NE) signature and c-Kit expression. Taken together,
these data underscore the contribution of MCs in tumor progression and uncover a new, opposite role of MCs in
protecting against the occurrence of aggressive NE variants in prostate cancer. Cancer Res; 71(18); 5987–97.
2011 AACR.
Introduction
In Western countries, prostate cancer accounts for the
second most frequent cause of death from cancer in men
(1). Prostatic carcinoma is often a multifocal disease, in which
multiple histologic patterns, reflective of the varied differen-
tiated aptitude of the neoplastic clone, may coexist within a
single tumor (2). Such a spectrum of histologic lesions
includes well-differentiated (WD) adenocarcinomas as well
as poorly differentiated (PD) or undifferentiated cancers.
Patients are classified and treated according to disease ex-
tension: those with organ-confined cancer undergo radical
prostatectomy or radiotherapy, whereas those with metastatic
or recurrent disease are subject to hormone therapy aimed at
androgen deprivation of malignant cells. Nonetheless, 18 to
36 months after an initial response to anti-androgen therapy,
most prostate carcinomas switch to a hormone-resistant
phenotype, entering into a more aggressive and ultimately
fatal stage of disease. Foci of neuroendocrine (NE) cells are
seen in virtually all cases of prostatic carcinoma; however, an
extensive NE differentiation is associated with androgen
independence, refractoriness to treatment, and poor progno-
sis (3).
The same heterogeneous histologic features of human
prostate cancer can be found in tumors from mouse counter-
parts, such as the transgenic adenocarcinoma of the mouse
prostate (TRAMP), in which SV40 large T antigen oncogene
expression, driven by the rat probasin promoter, induces
prostate transformation (4, 5). As in men, prostate cancers
of TRAMP mice may switch, upon castration, from slowly
growing adenocarcinoma to aggressive PD tumors with an NE
phenotype (6).
Mast cells (MC) are granulocytic immune cells best known
for their role in allergy and anaphylaxis, with important
functions in innate immunity against bacteria, viruses, and
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parasites. Since their first description in the late 19th century,
MCs were found aggregated around and within many types
of solid cancers, but only in recent years the multiple functions
operated by MCs in fostering angiogenesis, tissue remodeling,
and immunomodulation in human and murine cancer have
emerged. MCs may exert pro- or antitumoral roles, depending
on tumor type, on microenvironmental signals and on neigh-
boring interacting cells (7). Such functional complexity may
explain the discrepancy emerging from different studies,
showing opposite correlations of MC accumulation with
prognosis in different settings (8). In this scenario, prostate
cancer is no exception; several studies on human prostate
tumor samples have tried to address this issue (9–13), but no
conclusive data exist about the actual role of MCs in promot-
ing or suppressing cancer at this site. In a recent work,
peritumoral MCs were shown to enhance angiogenesis and
tumor growth in the orthotopic AT-1 rat prostate tumor
model and MCs were seen recruited in the peritumoral
compartment in men during the formation of androgen-
independent prostate cancer (14), recommending MCs as a
novel target for prostate tumor therapy. However, in the same
study, high MC numbers in the intratumoral compartment
were shown to be associated with a favorable outcome in
patients, implying that the actual role of MCs in prostate
cancer is indeed context dependent and that MC targeting has
to be carefully evaluated before being introduced into the
clinic.
Here, we analyze the role of MCs in transgenic mouse
prostate tumors and show that MCs exert different functions
according to the tumor subtype. We confirm that MCs are
essential players in the initial stages of prostate tumor pro-
gression, by supplying matrix metalloprotease 9 (MMP-9) in
the microenvironment, but become dispensable at post–ep-
ithelial-to-mesenchymal transition (EMT) stages. These data
are mirrored by MC distribution and MMP-9 expression in
tumor foci from human prostate biopsies. Moreover, we
provide the first evidence that MC inactivation may end up
with the paradoxical occurrence of fatal NE tumor variants, an
observation that must be taken into account before proposing
MC-targeted antitumor therapies.
Materials and Methods
Mice, tumor cell lines, and treatments
C57BL/6 mice were purchased from Charles River. c-Kit
mutant C57BL/6-KitW-sh/W-sh (KitW-sh) mice were purchased
from Jackson Laboratories and intercrossed twice to
C57BL/6, to obtain congenic C57BL/6-Kitþ/þ littermates to
be used as controls. TRAMP mice on C57BL/6 background
were kindly provided by Dr. Vincenzo Bronte (IRCCS Istituto
Oncologico Veneto, Padova, Italy), under agreement with Dr.
Norman Michael Greenberg (Fred Hutchinson Cancer Re-
search Center, Seattle, WA). MMP-9þ/ mice on C57BL/6
background were kindly provided by Dr. Leif Lund (Panum
Institute, Department of Experimental Medicine, University of
Copenhagen, Copenhagen, Denmark) and intercrossed to
obtain homozygous MMP-9/ mice. Mice were maintained
under pathogen-free conditions at the animal facility of
Fondazione IRCCS "Istituto Nazionale dei Tumori." Animal
experiments were authorized by the Institute Ethical Com-
mittee and carried out in accordance to institutional guide-
lines and national law (DL116/92).
Prostate tumor cell lines were obtained in our laboratory
from heterogeneous 28 to 32 weeks old prostatic adenocarci-
nomas from male TRAMP mice (as described in ref. 15).
Multiple lines were established on the basis of different growth
rates and cell morphology.
Wild-type and KitW-sh mice were injected with prostate
tumor cell lines (2  106 cells) subcutaneously in the flank,
and tumor growth was measured with a caliper once a week
and recorded as longest diameter  (shortest diameter)2 (in
cubic millimeters). In the orthotopic setting, 2  106 tumor
cells were inoculated in the prostate anterior lobe of wild-type
and KitW-sh mice. The growth of orthotopically injected tumor
lines and of spontaneous tumors in TRAMP mice was echo-
graphically monitored using a Vevo 770 micro-ultrasound
imaging system (Visualsonics Inc.), as described (16). The
invasive capacity of prostate lines was evaluated using the
Cell Invasion Assay Kit (Chemicon International) according to
manufacturer's instruction. Sodium cromoglycate (cromolyn;
Sigma-Aldrich) was intraperitoneally (i.p.) injected in mice
daily (10 mg/kg, dissolved in saline), starting 1 or 5 days after
tumor cell line injection (as indicated for each experiment), or
at 6 to 8 weeks of age in TRAMP mice, and continuing for the
duration of the experiment.
Histology, immunohistochemistry, and flow cytometry
Histopathologic and immunohistochemical analyses were
carried out on formalin-fixed and paraffin-embedded speci-
mens. MC distribution and density on mouse tissues were
estimated by staining slides with toluidine blue as previously
reported (17); MCs were counted out of 5 high-power micro-
scopic fields (400), and counts were expressed as average.
Immunohistochemistry and flow cytometry were carried
out as detailed in the Supplementary Material.
Human prostate cancer samples were gathered from the
archives of the Human Pathology Section of the University of
Palermo School of Medicine. Archival samples representative
of the whole spectrum of preneoplastic and neoplastic altera-
tions, namely glandular epithelial hyperplasia (n ¼ 5), pros-
tatic intraepithelial neoplasia (PIN)/in situ adenocarcinoma
(n ¼ 5), WD/moderately differentiated infiltrating adenocar-
cinoma (Gleason score 1–3; n ¼ 5), and PD/undifferentiated
carcinomas (Gleason score 4–5; n ¼ 6), were selected. MC
counts on human samples were carried out on sections
immunostained using an anti-human tryptase monoclonal
antibody (clone 10D11; Novocastra). The number of tryp-
tase-positive cells was counted out of 5 high-power micro-
scopic fields, and counts were expressed as average. All slides
were analyzed under a DM2000 optical microscope (Leica
Microsystems), and microphotographs were collected using a
DFC320 digital camera (Leica).
Stem cell factor, VEGF, and MMP-9 detection
Stem cell factor (SCF), VEGF, and MMP-9 were measured in
cell culture supernatants, mouse sera, or tumor tissue cultures
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by sandwich ELISA using the DuoSet ELISA Development
System for mouse SCF (R&D Systems), the Murine VEGF
Development Kit (Peprotech, Inc.), and the Quantikine Total
MMP-9 ELISA Kit (R&D System), respectively, according to
manufacturer's instruction. Sera from mice were collected as
previously described (18).
Bone marrow–derived MC differentiation and
reconstitution of KitW-sh mice
Bone marrow–derived MCs (BMMC) were obtained by in
vitro differentiation of bone marrow cells taken from mouse
femurs and tibias, in the presence of interleukin 3 and SCF (20
ng/mL each; Peprotech), as described (19). After 5 weeks of
culture, BMMCs were monitored for FceRI and c-Kit expres-
sion by flow cytometry, and purity was more than 90%.
BMMCs were obtained from pools of 3 to 4 mice in each
experiment. For MC reconstitution studies, BMMCs derived
from wild-type or MMP-9/ mice were transferred by intra-
dermal injection into 8 weeks old KitW-sh male mice (5  106
cells in 4  50 mL aliquots in PBS in a row down the length of
shaved left flank skin). Tumor cell lines were injected 6 to
8 weeks after adoptive transfer of BMMCs.
Gene expression profiling
RNA was isolated from prostate cell lines, prostates from
30 weeks old C57BL/6 mice, and spontaneous tumors from
30 weeks old TRAMP mice, 24 weeks old KitW-shTRAMP mice,
and 24 weeks old cromolyn-treated TRAMP mice, using the
guanidinium thiocyanate/cesium chloride gradient method
(20). mRNA expression profiles were analyzed on an Illumina
microarray platform as detailed in Supplementary Data. All
array data have been deposited in National Center for Bio-
technology Information's Gene Expression Omnibus (GEO)
and are accessible through GEO series accession number
GSE29958. Class comparison analysis to identify differentially
expressed genes between different tumor cell lines, or between
different TRAMP tumors, was carried out using the GenePat-
tern Software (Broad Institute-MIT; ref. 21). The program ran
a paired t test using the random variance model, and differ-
ences of expression with a value of P < 0.05 were considered
significant.
Statistical analysis
Results are expressed as the means  SD, unless differently
indicated. Comparisons between 2 groups were carried out
with the 2-tailed Student t test for unpaired samples, applying
correction for unequal variances when required. Tumor-take
curves were compared with the Mann–Whitney U test
(2-tailed). In all tests, the value of P < 0.05 was considered
significant.
Results
MCs are enriched and degranulated in areas of WD
adenocarcinoma but not in PD lesions in TRAMP
tumors
To evaluate MC infiltration in prostates from TRAMP
mice, we assessed the frequency of c-Kitþ FceRIþ cells among
prostatic CD45þCD11b cells by flow cytometric analysis at 16
to 18, 22 to 24, and 30 to 32 weeks of age. Very few c-Kitþ
FceRIþ cells could be detected in prostates from young
TRAMP mice, but their frequency increased up to 9% of
CD45þ cells in tumoral prostates from 30 to 32 weeks old
TRAMP mice and was significantly higher than that found in
age-matched wild-type prostates (Fig. 1A and B).
Toluidine blue staining of TRAMP prostates allows the
visualization of MCs in tumor areas and peritumoral tissue
at different stages of progression (Fig. 1D), classified according
to the Bar Harbor consensus report of prostate lesions in
genetically engineered mice (22). Prostate glands with signs of
slight epithelial hyperplasia did not show accumulation of
MCs in the stroma. However, an increased number of MCs
were observed at sites of atypical epithelial hyperplasia/PIN.
Such an increase became more conspicuous in areas of
adenocarcinoma, where clustered MCs showed signs of de-
granulation. Strikingly, MC number dropped dramatically in
PD/anaplastic foci (Fig. 1C and D).
These data show that MCs infiltrate spontaneous prostate
tumors and significantly increase in number upon tumor
progression from PIN to WD adenocarcinoma but are absent
around foci of PD/anaplastic adenocarcinoma.
Novel TRAMP tumor cell lines phenocopy WD and PD
prostate tumors also in terms of MC infiltration
To further analyze the functional role of MCs in prostate
tumors in relation to different histologic patterns, we derived
and characterized a set of novel tumor cell lines from pros-
tates of 28 and 32 weeks old TRAMP mice. These novel cell
lines were reflective of at least 2 distinct stages of tumor
progression, displaying in vitro either a distinctive epithelial
morphology (Fig. 2A, top inset) or a round-to-spindle mor-
phology (Fig. 2A, bottom inset). Two of these novel cell lines,
T1525 and T23, were selected as representative models of WD
and PD/anaplastic prostate tumors, respectively (Supplemen-
tary Fig. S1), and used in further experiments. All results were
then confirmed with at least one additional cell line per tumor
type (data not shown). Both cell lines were tumorigenic when
injected subcutaneously or orthotopically in adult C57BL/6
male mice. T1525, which maintained an epithelial morphol-
ogy, gave rise to adenocarcinomas characterized by a pseu-
doglandular structure, whereas T23, reflective of EMT,
originated tumor nodules mirroring PD/anaplastic TRAMP
cancers in terms of morphology (Fig. 2A).
MC infiltration in these tumors recapitulated our observa-
tions on spontaneous TRAMP prostate tumors; accordingly,
toluidine blue staining identified MCs infiltrating WD, but not
PD tumors (Fig. 2B and C). This was not due to a generic lack
of bystander infiltrating cells in PD nodules, because staining
with anti-CD3 showed no significant difference in T-cell
infiltrate between WD and PD tumors (Supplementary
Fig. S2). Notably, WD T1525, but not PD T23 cell line, was
found to produce the c-Kit ligand SCF, in both membrane-
bound and secreted form (Supplementary Fig. S3A and B).
In addition, SCF was detected in the sera of T1525, but
not T23, tumor-bearing mice at concentrations directly
correlating with tumor volume (Supplementary Fig. S3C).
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Taken together, these data show a strong association
between high MC infiltrate and prostate adenocarcinomas,
likely because of their SCF secretion. Such an association is
not found in PD cancers, which have undergone EMT.
MCs are both necessary and sufficient for WD prostate
tumor growth
Two different mouse models of spontaneous/inducible
carcinogenesis, affecting areas other than the prostate,
showed infiltration of MCs in early lesions (23, 24). In both
models, MCs played a causative role in tumor development
by releasing inflammatory molecules promoting neoangio-
genesis and tumor invasiveness. To verify whether MCs
have a protumorigenic role in the early phases of prostate
carcinogenesis, we blocked MC function by using both
pharmacologic and genetic approaches. Sodium cromogly-
cate (cromolyn) inhibits MC degranulation and release of
inflammogens (25). We injected the WD line T1525 subcu-
taneously in male wild-type mice and, when tumors were
palpable, we treated mice daily with cromolyn for 3 weeks, a
treatment that significantly inhibited tumor growth
(Fig. 3A). If the treatment began the same day of tumor
injection, it completely prevented tumor onset in most mice
(data not shown). Cromolyn did not show a direct inhib-
itory effect on T1525 tumor growth in vitro (data not
shown).
To validate independently the essential contribution of MCs
in prostate tumorigenesis, we took advantage of MC-deficient
KitW-sh mutant mice. These mice carry a genetic inversion in
the Kit gene promoter, which breaks a positive element
controlling c-Kit expression specifically in MCs, and exhibit
therefore profound MC deficiency in multiple organs, includ-
ing dermis and prostate (26). In line with results obtained with
cromolyn treatment, the WD line T1525 failed to grow in 90%
of KitW-sh mutant mice when injected either subcutaneously
(Fig. 3B) or orthotopically (Fig. 3D and E). To rule out that cells
other thanMCs, whichmay be affected by the KitW-shmutation
(27), might contribute to cancer outgrowth, we generated an
MC knock-in system by locally reconstituting KitW-sh mice
with wild-type BMMCs and assessing MC ability to restore
tumor growth. A total of 5  106 BMMCs were intradermally
injected in the left flank of KitW-sh mice. Two months later,
reconstituted mice were injected in the same flank with T1525
tumor cells. In these mice, tumors did develop with an
incidence and kinetics similar to wild-type controls, whereas
no tumors developed in the majority of non-reconstituted
KitW-sh mice (Fig. 4D). Consistently with the positive outcome
of MC injection, tumors from reconstituted mice were richly
infiltrated by MCs (Supplementary. Fig. S4).
Of note, PD tumor line T23 grew in KitW-sh mice as well as in
wild-type controls (Fig. 3C), indicating its independence from
MCs for growth.
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Figure 1. MCs are enriched and degranulated in areas of WD adenocarcinoma, but not in PD lesions, in TRAMP tumors. A, mean percentages of MCs
infiltrating prostates from TRAMP mice and nontransgenic controls [wild-type (wt)] at different ages (3 mice/group). MCs were identified by flow cytometry as
CD45þCD11b c-Kitþ FceRIþ cells. B, representative plots of prostate-infiltrating MCs in wt and TRAMP mice at 30 to 32 weeks of age. C, MC counts
carried out on toluidine blue–stained prostate sections from TRAMP mice of different ages, characterized by normal prostatic epithelium (NP), epithelial
hyperplasia (hyp), PIN, overt adenocarcinoma (AC), and anaplastic foci (anapl). Three to 7 samples per histologic type were analyzed. D, toluidine blue
staining of representative samples from TRAMP mice as in (C). Arrows indicate MCs. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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Taken together, these data show that MCs are both nec-
essary and sufficient for the growth of WD but dispensable for
PD prostate tumors.
MCs favor the growth of WD adenocarcinoma through
MMP-9 production
According to a model proposed on epithelial carcinogen-
esis (23), we hypothesized that WD, but not PD, prostate
tumors might depend on MCs for provision of factors favor-
ing angiogenesis and tumor invasiveness. Indeed, MCs are a
source of VEGF, basic fibroblast growth factor, and TNF-a
(28). They also produce MMP-9 (ref. 29; Supplementary
Fig. S5A), a matrix-degrading enzyme-promoting tumor
invasiveness. MMP-9 is also crucially involved in the mobi-
lization of bioactive VEGF from the extracellular matrix
(ECM; ref. 18), helping the switch from vascular quiescence
Figure 2. Novel TRAMP tumor
cell lines phenocopying WD
and PD prostate tumors are
differentially infiltrated by MCs.
A, representative Masson's
trichrome and (B) toluidine blue
staining of tumors originated by
subcutaneous injection of T1525
(top) and T23 (bottom) cells in
wild-type mice. Insets in
(A) show hematoxylin and eosin
staining of T1525 (top) and T23
(bottom) cell cultures in vitro.
Arrows indicate infiltrating
MCs. C, MC counts carried
out on toluidine blue–stained
sections from 3 T1525 and 3 T23
tumors. ***, P < 0.005.
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Figure 3. MCs are both necessary and sufficient to promote WD prostate tumor growth. A, tumor size ( SEM) in wild-type (wt) mice injected
subcutaneously with T1525 cells and treated daily with either cromolyn or saline from day 5 after injection. One representative of 3 independent experiments
(7 mice/group) is shown. B, tumor take of Kitþ/þ (wt) and KitW-sh mice injected subcutaneously with T1525 cells or (C) T23 cells. Pools of 2 independent
experiments (7–10 mice/group) are shown. D, tumor size ( SEM) in wt and KitW-sh mice with intraprostatic injection of T1525 cells and evaluated
echographically (7mice/group). E, echographic imaging of the only tumor grown inKitW-shmice of 7 injected orthotopically in comparison with 1 representative
tumor grown in wt mice (100% tumor take). White lines outline tumor mass. *, P < 0.05; **, P < 0.01; ***, P < 0.005. ns, not significant.
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to neoangiogenesis. Notably, the mature form of MMP-9
localizes within the secretory granules of MCs (30); there-
fore, its secretion is inhibited by cromolyn treatment. We
hypothesized that, upon progression and EMT, prostate
tumors become MC-independent, thanks to a newly
acquired ability to produce protumoral factors. We therefore
interrogated gene expression profiles of WD and PD tumor
cell lines to identify genes encoding factors involved in
angiogenesis and invasion and found that Vegf and Mmp9
were upregulated in PD compared with WD tumors (3- and
2.44-fold, respectively), a finding confirmed at the protein
level by assessing VEGF and MMP-9 molecules in culture
supernatants (Fig. 4A). The inability to produce MMP-9
by WD line T1525 in vitro prompted us to verify whether
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in vitro measured by ELISA after
48 hours of culture. N.D., not
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from TRAMP tumors. D, tumor
take of T1525 line injected
subcutaneously in wt, KitW-sh, and
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BMMCs. One representative of
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this factor is provided by tumor-infiltrating stromal cells
in vivo. Culture supernatants of excised WD T1525 tumor
tissue ex vivo contained very high levels of MMP-9 (Fig. 4B).
Immunohistochemistry (IHC) analysis confirmed that
MMP-9 was diffusely expressed by T23 neoplastic cells
whereas it was absent in T1525 neoplasms. Rather, in
T1525 tumors, MMP-9 was focally expressed by scattered
cells, whose morphology and distribution were consistent
with that of infiltrating MCs (Fig. 4C, top). This feature was
reproduced in TRAMP mice (Fig. 4C, bottom), where scat-
tered MCs accounted for MMP-9–expressing cells in WD
cancer foci whereas cancer cells expressing directly MMP-9
were only found in PD foci.
In vitro, invasiveness through a basement membrane
required MMP-9; accordingly, PD T23 cells were invasive
whereas T1525 cells were not, unless in the presence of
supernatant from activated wild-type, but not MMP-9/,
BMMCs (Supplementary Fig. S5B). To confirm, in vivo, that
the role of MCs in promoting WD prostate tumor growth
relied on their MMP-9 production, we derived BMMCs from
MMP-9/ mice to reconstitute KitW-sh mice. Although
purity and dermal reconstitution efficiency of BMMCs were
equal for MMP-9/ and wild-type BMMCs (not shown), the
injection of T1525 cells produced tumors only in KitW-sh mice
reconstituted with wild-type, but not with MMP-9/,
BMMCs (Fig. 4D).
Collectively, these results indicate that MCs support WD
prostate tumors by producing MMP-9.
Human prostate carcinoma samples display the same
pattern of MC infiltration and MMP-9 expression of
TRAMP tumors
To explore whether MCs producing MMP-9 might also
associate with adenocarcinomas arising in human prostate,
5 WD (Gleason score 2–3) and 6 PD (Gleason score 9–10)
prostate cancers were investigated for the amount and
distribution of tryptase-positive MCs and MMP-9 expression
by IHC. Notably, neoplastic foci from WD cancers were
populated by a relevant amount of tryptase-positive cells,
found in close contact with cytokeratin-stained cancer cells.
PD cancers, conversely, showed only very few scattered tryp-
tase-positive MCs infiltrating the neoplastic foci (Fig. 5A and
B). Coherently with the dynamics observed in mice, MMP-9
expression proved to be almost entirely confined to MCs in
WD human prostate cancers whereas it was found in the
neoplastic cells of PD ones (Fig. 5C). Altogether, these data
support the extension of the proposed role of MCs in fostering
the development and progression of mouse prostate adeno-
carcinomas to the human pathologic setting.
MC targeting in TRAMP mice gives rise to aggressive NE
tumors expressing c-Kit
The aforementioned data suggested to test whether MC
targeting could hamper prostate tumorigenesis in the
TRAMP model. Cromolyn (10 mg/kg i.p.) was given to
TRAMP mice daily, starting from 6 to 8 weeks of age until
24 weeks of age, and tumor growth was monitored using
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Figure 5. Human prostate carcinoma samples display the same pattern of MC infiltration and MMP-9 expression of TRAMP tumors. A, IHC double
staining for MC tryptase (purple signal) and cytokeratin (brown signal) of representative samples of human biopsies characterized by atypical epithelial
hyperplasia/PIN, WD or moderately differentiated (MD) adenocarcinoma, and PD adenocarcinoma. B, MC counts carried out on tryptase-stained sections
from 5 WD (Gleason score 2–3) and 6 PD (Gleason score 9–10) cases classified according to histologic type. hyp, epithelial hyperplasia. C, IHC staining for
MMP-9 of representative samples of human WD adenocarcinoma (left) and PD adenocarcinoma (right).
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noninvasive 3-dimensional ultrasound imaging technology
as previously described (16). Strikingly, in TRAMP mice
chronically treated with cromolyn, fast growing isoechoic
prostatic tumors originating in the ventral lobe were de-
tectable in approximately 50% of mice already at 18 weeks of
age and mice had to be sacrificed at 24 weeks of age because
of excessive tumor burden. The remaining 50% had no
detectable tumor masses by ultrasound imaging carried
out at 18 and 24 weeks of age. Histologically, the rapidly
growing tumors were characterized by sheets of highly
anaplastic cells (Fig. 6A) whereas the prostates without
tumor at echographic inspection showed, at worst, signs
of glandular epithelial hyperplasia and/or foci of locally
infiltrating adenocarcinoma (not shown). Similarly, early
anaplastic tumors arose from the ventral prostate in 50%
of KitW-shTRAMP double mutants. This increased occurrence
of early anaplastic tumors was clearly associated with MC
inactivation/depletion, in view of an overall incidence of
similar tumors in less than 10% of all TRAMP mice in our
colony (Fig. 6B). Gene expression profiles of these tumors
compared both with TRAMP adenocarcinomas and with
normal prostates excluded early EMT while underscored a
marked NE differentiation (Fig. 6C). Genes upregulated in
tumors from cromolyn-treated TRAMP mice were signifi-
cantly enriched for genes (listed in bold) belonging to a
published "NE prostate tumor molecular signature,"
obtained by integration of expression profiles of NE tumors
from Cr2-TAg mice (31) and human patients (ref. 32; indi-
cated by red dots in Fig. 6E). Accordingly, tumors from
cromolyn-treated TRAMP (Fig. 6D, top) and KitW-shTRAMP
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Figure 6. MC targeting in TRAMP mice gives rise to aggressive c-Kit–expressing NE tumors. A, representative macroscopic appearance (macro; top) and
hematoxylin and eosin (H&E) staining (bottom) of tumors developed in TRAMP and in cromolyn-treated TRAMP mice. B, incidence of anaplastic
tumors (calculated as the number of mice developing anaplastic tumors/total mice) arising in TRAMP, cromolyn-treated TRAMP, and KitW-shTRAMP mice
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mice compared with 30 weeks old wild-type (B6) and TRAMP prostates. Red and blue indicate relative expression superior or inferior to the gene-wise
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mice (not shown) showed extensive and uniform expression
of the neuronal marker synaptophysin.
In view of the stem cell origin hypothesis of NE tumors in
TRAMP mice (33, 34) and of c-Kit expression by prostate stem
cells (35), we tested whether the tumors from cromolyn-
treated TRAMP and KitW-shTRAMP mice expressed the c-Kit
receptor (Fig. 6D, bottom); accordingly, c-Kit staining was
restricted to MCs scattered in prostate adenocarcinomas in
TRAMP mice whereas diffused and homogenously expressed
at significant levels by tumor cells in cromolyn-treated
TRAMP mice (Fig. 6D, bottom). Also, tumoral c-Kit was
detected in KitW-shTRAMP mice (Supplementary Fig. S6),
indicating that the KitW-sh mutation does not affect c-Kit
expression by prostate cells. Interestingly, Kit gene was part
of the published NE molecular signature, indicating it as a
common trait of prostate NE tumors.
Together, these results show that MC functional inactiva-
tion or genetic ablation in TRAMP mice results in high
incidence of early-onset c-Kitþ NE tumors.
Discussion
The study of the role of MCs in prostate tumorigenesis is
complicated by the multifocality of prostate cancer, in which
several tumor foci with different molecular and proliferative
characteristics may originate and coevolve within the same
organ. We have found that MCs infiltrating prostate tumors in
TRAMP mice and humans increase in number upon disease
progression. This and other findings (12, 36) would indicate
that the inhibition of MC functions could be a new treatment
of early-stage prostate cancer. However, our fine analysis of
the complex relations existing between MCs and prostate
tumors indicates an actual risk for more aggressive tumors
in case MCs are depleted/inactivated.
We established new tumor cell lines phenocopying the
different histologic and functional features of TRAMP tumors
and showed that MCs promote tumor growth of WD adeno-
carcinoma by providing MMP-9. This finding fostered the idea
of MC targeting as a way to impair tumor growth, which is also
in line with a study carried out in rats showing that peritu-
moral MCs stimulate prostate tumor growth by providing
proangiogenic factors (14).
MMP-9–producing cells of bone marrow origin have been
shown to promote skin squamous carcinogenesis (37). MMP-9
has been indicated to correlate with progression of prostate
tumor in humans (38) while excluded to have a role in the
induction of NE tumors in the Cr2-TAg mouse model (39).
Degrading the ECM, MMP-9 confers a more permissive envi-
ronment for cell migration and invasion and provides the
enzymatic cleavage necessary for release and activation of
growth factors.
In contrast, PD prostate tumors showing features of
EMT produce MMP-9 autocrinously and are devoid of
infiltrating MCs both in mouse and in humans. Their MC
independence may imply that MC inactivation would be
ineffective in the therapy for advanced tumors. Moreover,
this finding points to the critical need of indicating the
exact Gleason score when prognosis is correlated to MC
density, otherwise discrepancies between different studies
may emerge (12, 13).
When MC targeting was applied to transgenic prostate
tumors, by treating TRAMP mice chronically with cromolyn
(from 6–8 weeks of age, well before the earliest evidence of
disease) or by crossing TRAMP mice with KitW-sh mice, we
paradoxically increased the occurrence of aggressive prostate
tumors, identifiable already at 18 weeks of age. These tumors
displayed the molecular and histologic features of overt NE
differentiation. NE cells are part of the normal prostate epi-
thelium, together with luminal (secretory) and basal cells. NE
and secretory cells arise both from a commonprogenitor, adult
prostate stem cell, which persists in the adult organ, most
probably confinedwithin thebasal cell compartment (35, 40). In
the TRAMPmodel, SV40 TAg initiates transformation not only
in luminal cells but also in prostate stem cells, because both
components are androgen responsive. Current models of pros-
tatic tumorigenesis propose that,whereas epithelial tumors are
derived from the proliferation of transformed luminal cells, NE
carcinomas arise independently by the NE transdifferentiation
of transformed prostate stem cells (33, 34). These indications
suggest that, inMC-targetedTRAMPmice, thehigher incidence
of NE prostate tumors might derive from the dysregulation of
prostate stem cells. A possible explanation comes from the
expression of c-Kit receptor, which is common to prostate stem
cells (35) and to resident MCs, scattered in the stroma sur-
rounding prostatic glands. Both cell types are dependent on the
availability of the common SCF ligand to function correctly;
MCs require SCF for survival and functional activation,whereas
prostate stem cells apparently require c-Kit signaling for pros-
tate regeneration (35). It is tempting to speculate that a
previously unrecognized MC role may be the maintenance of
prostate stemcell homeostasis by keeping local SCF availability
in check; MCs may control NE tumor formation, serving as
"natural decoys" that sequester SCF, thus limiting c-Kit signal-
ing in TAg-transformed prostate stem cells. According to this
hypothesis, c-Kitþ NE tumors would be more likely to develop
in the absence of MCs, or upon cromolyn treatment, which
some groups have reported to hamper MC migration in re-
sponse to nonhomeostatic stimuli (41). The concept of com-
pensatory mechanisms existing between c-Kit–dependent
cellular populations is corroborated by our data showing that
MC reconstitution normalizes the enhanced granulocytosis
characterizing KitW-sh mice (17). Our hypothesis is also sup-
portedby recent results showingcompetitionbetweenprostate
cancer cells and hematopoietic stem cells for the endosteal
niche in the bone marrow (42); intriguingly, cancer cells were
more competitive when expressing "stem-like" features, sug-
gesting a potential competition for SCF, as both cancer and
hematopoietic stem cells are expectedly c-Kitþ.
The novel role ofMCs in protecting against the development
of "stem-like" tumors might find correlation in humans, where
NE differentiation occurs in 10% to 30% of prostate cancers,
especially after hormone ablation and where tumoral c-Kit
expression has been identified in a sizeable fraction of high-risk
human prostate tumors (43). A similar mechanism of tumor
control by MCs may be envisaged also for other nonmutated
c-Kit–expressing tumors, such as Merkel carcinoma (44).
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Taken together, our data underscore the crucial role of
MCs in prostate tumorigenesis and show that MCs exert
different functions according to tumor stage; MCs favor
initial tumor growth providing MMP-9 but become dispens-
able after EMT. We also uncover a new role for MCs in
suppressing the occurrence of c-Kitþ NE tumors and point
to a detrimental effect of mere MC inhibition. In this view, c-
Kit tyrosine kinase inhibitors, such as imatinib, would
instead offer the advantage of targeting both adenocarcino-
ma-promoting MCs (stroma targeting) and NE tumor var-
iants (tumor targeting; ref. 45).
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